Four New Phenotype MicroArray Panels
Completed for use in Functional Genomics and Drug Discovery
Hayward, CA - January 9, 2001 Biolog, Inc., a biotechnology
company pioneering powerful new tools for cell-based analysis, announced
today that it has completed development of four additional Phenotype
MicroArray (PM) panels. These new panels bring the total number
of cell-based assays available in the PM format to 760.
PMs are designed to study a range of cell properties
(phenotypes) as a means of understanding how a gene or a drug affects
living cells - a critical step in identifying potential new drug
targets and in developing safe and effective new drugs. Biolog's
proprietary PM technology provides researchers with powerful, efficient
and cost-effective information for determining gene function by
directly measuring the consequence of a genetic change on cellular
phenotypes. This technology allows researchers to test hundreds
to thousands of cell properties simultaneously, and also has applications
in validating and optimizing drug targets, determining a drug's
mode of action, assessing toxicology, and basic cellular research.
The patented method involves the use of PMs to conduct
a very detailed comparison of two cell lines, one of which has been
modified by a gene mutation or tested with a drug lead. Data generated
from the MicroArrays are captured and interpreted by Biolog's OmniLog®
PM System, which uses bioinformatic software to report how the cells
have changed. An advantage of the PM technology is its ability to
detect many unexpected changes in cell function as easily as a singular
The PM panels now include 190 assays to monitor carbon
metabolism, 380 assays to monitor nitrogen metabolism, 95 assays
to monitor sulfur and phosphorus metabolism, and 95 assays to monitor
growth stimulation by different nutrients. Eventually, Biolog plans
to offer 2,000 unique assays in the PM format for cellular analysis.
This will require the release of approximately 1,200 additional
assays, which is scheduled for later this year.
Currently the Phenotype MicroArray technology is optimized
for use with bacteria and fungal cells. The company has developed
procedures that facilitate analysis of the most important bacterial
infectious disease agents, and has begun work on fungal pathogens.
The company will soon begin work to apply the PM technology to mammalian
Biolog is a pioneer in the development of powerful
new cellular analysis tools for solving critical problems in pharmaceutical
and biotechnology research and development. The company has recently
launched its Phenotype MicroArray technology and OmniLog® PM System
for such applications as determining gene function, validating and
optimizing drug targets, and assessing cellular toxicology. Further
information can be obtained at the company's website, www.biolog.com.